Disc Medicine appoints Pamela Stephenson as CCO; grants inducement equity award

Disc Medicine, Inc.

Pamela Stephenson, MPH, named Chief Commercial Officer effective Feb 26, 2024.
Stephenson has 25+ years biopharma experience, most recently CCO of Albireo (acquired by Ipsen).
Inducement award: option to purchase 55,000 shares and RSU for 36,666 shares under Nasdaq Rule 5635(c)(4).
Option vests 25% on first anniversary, then monthly; RSU vests in four equal annual installments.
Company is clinical-stage biopharma focused on serious hematologic diseases (NASDAQ:IRON).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.